G. Vassal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
G. Vassal has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Olivier Hartmann
Pediatrics Department, Institut Gustave Roussy, Villejuif, France
5 shared publications - Dominique Valteau-Couanet
Pediatrics Department, Institut Gustave Roussy, Villejuif, France
4 shared publications E Benhamou
3 shared publicationsF. Doz
3 shared publicationsM Bonnay
3 shared publicationsJ Grill
Départment de pédiatrie, Institut Gustave-Roussy, 94805 Villejuif Cedex
2 shared publications
Latest Publications
- 18 November 2015
- Published by Elsevier in Archives de Pédiatrie
- Vol. 22 (12) , 1217-1222
Multidisciplinarité et formation des spécialistes à l’oncologie et à l’hématologie maligne pédiatrique
- 18 November 2015
- Published by Elsevier in Archives de Pédiatrie
- Vol. 22 (12) , 1217-1222
Multidisciplinarité et formation des spécialistes à l’oncologie et à l’hématologie maligne pédiatrique
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15_suppl) , 10028
Phase I-II clinical and pharmacokinetic study of plitidepsin in children with malignant tumors. On behalf of the European ITCC (Innovative Therapies for Children with Cancer) Consortium
10028 Background: Plitidepsin (Aplidin) is a cyclic depsipeptide isolated from the tunicate Aplidium albicans, nowadays manufactured by synthesis. It is a rapid and potent inductor of apoptosis. Phase I trials in adults with solid and hematological malignancies explored 5 different treatment schedules. Muscle and liver toxicities were dose-limiting toxicities (DLTs); hematological DLT was not observed at the recommended dose (RD). Methods: This is a multicentre, open-label, non-randomized phase I-II two-step study in children with solid tumors with a dose finding stage followed by an expanded cohort at the RD. Plitidepsin was administered as a 3-h iv infusion every 2 weeks (1 injection=1cycle). The initial dose level was 4 mg/m2 (80% of the RD in adults), with a classical dose-escalation methodology to 5 and 6 mg/m2. Results: 37 patients (pts) have been enrolled to date. Median age was 9 years (range 2–17). 114 cycles in 33 pts were evaluable for toxicity. During the dose finding stage 8 pts were treated at 4 mg/m2 (1 DLT, G2 myalgia lasting more than 2 weeks), 3 pts at 5 mg/m2 (no DLT) and 7 pts at 6 mg/m2 (2 DLTs, G4 CPK increase and G3 increase of ALT lasting more than 2 weeks). 6 mg/m2 was considered the maximum tolerated dose (MTD). 15 pts were further treated at the expanded cohort at 5 mg/m2. 2 pts had G3 vomiting, 1 pt G3 myalgia and dysesthesia, 1 pt G3 ALT increase for more than 2 weeks, and 2 pts G3 and G4 increases of CPK, respectively. Biochemical DLTs were asymptomatic. Non-hematological toxicities included G1-G2 muscle disorders (myalgia, CPK elevation, muscle weakness) and G1–2 fatigue. 3 G3 hypersensitivity reactions were observed, 1 without adequate prophylactic treatment. Pharmacokinetic data were similar to those reported in adults (extensive tissue distribution, long half-life), however children of the age group 2–11 years appeared to have lower clearance. Clinical activity was observed in pts with neuroblastoma (1PR, 1SD), glioblastoma, pancreatoblastoma, medulloblastoma and hepatoblastoma (1 SD each). Conclusions: Plitidepsin was well tolerated in children, with muscular disorders being the most relevant toxicity observed. 6 mg/m2 was defined as MTD.
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15_suppl) , 10028
Phase I-II clinical and pharmacokinetic study of plitidepsin in children with malignant tumors. On behalf of the European ITCC (Innovative Therapies for Children with Cancer) Consortium
10028 Background: Plitidepsin (Aplidin) is a cyclic depsipeptide isolated from the tunicate Aplidium albicans, nowadays manufactured by synthesis. It is a rapid and potent inductor of apoptosis. Phase I trials in adults with solid and hematological malignancies explored 5 different treatment schedules. Muscle and liver toxicities were dose-limiting toxicities (DLTs); hematological DLT was not observed at the recommended dose (RD). Methods: This is a multicentre, open-label, non-randomized phase I-II two-step study in children with solid tumors with a dose finding stage followed by an expanded cohort at the RD. Plitidepsin was administered as a 3-h iv infusion every 2 weeks (1 injection=1cycle). The initial dose level was 4 mg/m2 (80% of the RD in adults), with a classical dose-escalation methodology to 5 and 6 mg/m2. Results: 37 patients (pts) have been enrolled to date. Median age was 9 years (range 2–17). 114 cycles in 33 pts were evaluable for toxicity. During the dose finding stage 8 pts were treated at 4 mg/m2 (1 DLT, G2 myalgia lasting more than 2 weeks), 3 pts at 5 mg/m2 (no DLT) and 7 pts at 6 mg/m2 (2 DLTs, G4 CPK increase and G3 increase of ALT lasting more than 2 weeks). 6 mg/m2 was considered the maximum tolerated dose (MTD). 15 pts were further treated at the expanded cohort at 5 mg/m2. 2 pts had G3 vomiting, 1 pt G3 myalgia and dysesthesia, 1 pt G3 ALT increase for more than 2 weeks, and 2 pts G3 and G4 increases of CPK, respectively. Biochemical DLTs were asymptomatic. Non-hematological toxicities included G1-G2 muscle disorders (myalgia, CPK elevation, muscle weakness) and G1–2 fatigue. 3 G3 hypersensitivity reactions were observed, 1 without adequate prophylactic treatment. Pharmacokinetic data were similar to those reported in adults (extensive tissue distribution, long half-life), however children of the age group 2–11 years appeared to have lower clearance. Clinical activity was observed in pts with neuroblastoma (1PR, 1SD), glioblastoma, pancreatoblastoma, medulloblastoma and hepatoblastoma (1 SD each). Conclusions: Plitidepsin was well tolerated in children, with muscular disorders being the most relevant toxicity observed. 6 mg/m2 was defined as MTD.
- 1 June 2005
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (16) , 8535
A new IV busulfan fixed dosing for better exposure targeting in children undergoing allogeneic or autologous hematopoietic stem cell transplantation
8535 Background: Oral busulfan (Bu) clearance is highly variable in children and increased in the youngest. Thus, higher doses in children ≤4 y allowed to reach a similar exposure (AUC). Nevertheless, therapeutic drug monitoring (TDM) and dose-adjustments are needed to control the Bu AUC variability. An IV Bu form was developed. In a first trial, 24 children received an IV Bu dosing equivalent to the oral one (1.0 mg/kg ≤ 4 y, 0.8 mg/kg > 4 y). A retrospective pharmacokinetic (PK) modelling demonstrated body weight (BW) better than age for dose calculation. A new dosing was developed. [Nguyen L. et al., BMT 2004] Methods: It was evaluated in a representative pediatric population receiving Bu/Melphalan or Bu/Cyclophosphamide as a conditioning regimen before autologous or allogeneic transplantation, respectively. No dose adjustment was allowed and PK was performed at doses 1, 9 and 16. Bayesian Bu AUCs were calculated. Results: Today’s results (55 patients, median age 6 y [0.3 - 17.2], 20 patients ≤ 4 y) demonstrated the dosing performance to target the “therapeutic window”. All AUCs were >847 μM.min (engraftment threshold), 84% <1500 μM.min (hepatic veno-occlusive disease threshold) and all <2100 μM.min. Advantage of this new dosing over the previous age-based one is obvious. Large inter-patient variability (CV = 50%) on Bu clearance was confirmed but similar AUCs were achieved whatever the age. AUC inter-patient variability was 2.5-fold-reduced (CV ≤ 20%). Low intra-patient variability enabled reproducible exposure without the constraining and invasive use of TDM in children. Preliminary clinical results supported the PK benefit of the new IV Bu dosing: all patients engrafted, no death at Day+100 post-transplant, no severe HVOD (McDonald criteria). Conclusions: Body-weight-based calculation of IV Bu fixed dose can successfully target a therapeutic AUC in children without any dose-adjustment and PK monitoring. No significant financial relationships to disclose.
- 1 June 2005
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (16) , 8535
A new IV busulfan fixed dosing for better exposure targeting in children undergoing allogeneic or autologous hematopoietic stem cell transplantation
8535 Background: Oral busulfan (Bu) clearance is highly variable in children and increased in the youngest. Thus, higher doses in children ≤4 y allowed to reach a similar exposure (AUC). Nevertheless, therapeutic drug monitoring (TDM) and dose-adjustments are needed to control the Bu AUC variability. An IV Bu form was developed. In a first trial, 24 children received an IV Bu dosing equivalent to the oral one (1.0 mg/kg ≤ 4 y, 0.8 mg/kg > 4 y). A retrospective pharmacokinetic (PK) modelling demonstrated body weight (BW) better than age for dose calculation. A new dosing was developed. [Nguyen L. et al., BMT 2004] Methods: It was evaluated in a representative pediatric population receiving Bu/Melphalan or Bu/Cyclophosphamide as a conditioning regimen before autologous or allogeneic transplantation, respectively. No dose adjustment was allowed and PK was performed at doses 1, 9 and 16. Bayesian Bu AUCs were calculated. Results: Today’s results (55 patients, median age 6 y [0.3 - 17.2], 20 patients ≤ 4 y) demonstrated the dosing performance to target the “therapeutic window”. All AUCs were >847 μM.min (engraftment threshold), 84% <1500 μM.min (hepatic veno-occlusive disease threshold) and all <2100 μM.min. Advantage of this new dosing over the previous age-based one is obvious. Large inter-patient variability (CV = 50%) on Bu clearance was confirmed but similar AUCs were achieved whatever the age. AUC inter-patient variability was 2.5-fold-reduced (CV ≤ 20%). Low intra-patient variability enabled reproducible exposure without the constraining and invasive use of TDM in children. Preliminary clinical results supported the PK benefit of the new IV Bu dosing: all patients engrafted, no death at Day+100 post-transplant, no severe HVOD (McDonald criteria). Conclusions: Body-weight-based calculation of IV Bu fixed dose can successfully target a therapeutic AUC in children without any dose-adjustment and PK monitoring. No significant financial relationships to disclose.
- 1 August 2000
- Vol. 6 (8) , 3327-33
In vivo potentiation of radiation response by topotecan in human rhabdomyosarcoma xenografted into nude mice.
The lack of new highly efficacious drugs for cancer treatment promotes the search for innovative therapeutic modalities. The authors reported the results leading to the definition of parameters needed to demonstrate a possible radiopotentiation by topotecan (TPT) on two representative human rhabdomyosarcomas (RMSs) xenografted into nude mice. Experimental studies of radiopotentiation with different doses of topotecan showed that concomitant association of topotecan and RT for 5 consecutive days provided a synergistic therapeutic effect. Response rates were statistically higher with the radiochemotherapeutic combination (P < 0.001). Efficacy enhancement factors of this combination compared with the sum of the antitumoral activity of these treatments separately administrated were 1.54 and 1.60, respectively, on both rhabdomyosarcomas. Moreover, the efficiency of the combination of radiotherapy at the dose of 20 Gy with topotecan (12.5 mg/kg) was not statistically different from that of radiotherapy at the dose of 40 Gy. According to microscopy results, the analyses performed at different periods after topotecan treatment alone, radiotherapy alone, and their combination seemed to show that tumoral repopulation by malignant cells is as fast as the dose of radiotherapy and/or topotecan is low. Furthermore, lesions observed with the dose of 40 Gy were similar to those obtained with the association of topotecan at the dose of 12.5 mg/kg and radiotherapy at the dose of 20 Gy. In conclusion, all clinical and pathological results are consistent with a radiopotentiation effect of topotecan on the two xenografted human rhabdomyosarcomas and are currently leading to the design of clinical studies.
- 1 August 2000
- Vol. 6 (8) , 3327-33
In vivo potentiation of radiation response by topotecan in human rhabdomyosarcoma xenografted into nude mice.
The lack of new highly efficacious drugs for cancer treatment promotes the search for innovative therapeutic modalities. The authors reported the results leading to the definition of parameters needed to demonstrate a possible radiopotentiation by topotecan (TPT) on two representative human rhabdomyosarcomas (RMSs) xenografted into nude mice. Experimental studies of radiopotentiation with different doses of topotecan showed that concomitant association of topotecan and RT for 5 consecutive days provided a synergistic therapeutic effect. Response rates were statistically higher with the radiochemotherapeutic combination (P < 0.001). Efficacy enhancement factors of this combination compared with the sum of the antitumoral activity of these treatments separately administrated were 1.54 and 1.60, respectively, on both rhabdomyosarcomas. Moreover, the efficiency of the combination of radiotherapy at the dose of 20 Gy with topotecan (12.5 mg/kg) was not statistically different from that of radiotherapy at the dose of 40 Gy. According to microscopy results, the analyses performed at different periods after topotecan treatment alone, radiotherapy alone, and their combination seemed to show that tumoral repopulation by malignant cells is as fast as the dose of radiotherapy and/or topotecan is low. Furthermore, lesions observed with the dose of 40 Gy were similar to those obtained with the association of topotecan at the dose of 12.5 mg/kg and radiotherapy at the dose of 20 Gy. In conclusion, all clinical and pathological results are consistent with a radiopotentiation effect of topotecan on the two xenografted human rhabdomyosarcomas and are currently leading to the design of clinical studies.
- 30 September 1997
- Published by Elsevier in European Journal of Cancer
- Vol. 33, S249
1126: Phase I trial of Irinotecan (CPT-11)I in childhood solid tumours
- 30 September 1997
- Published by Elsevier in European Journal of Cancer
- Vol. 33, S249
1126: Phase I trial of Irinotecan (CPT-11)I in childhood solid tumours
- 1 August 1996
- Vol. 18 (2) , 325-32
Previous conventional chemotherapy is the principal risk factor for immunoglobulin deficiency during the early post-ABMT period in children.
Humoral immunodeficiency after ABMT may worsen the course of infectious complications as already described in this clinical setting; children with low Ig values of the three isotypes during the first week after ABMT experienced more severe infections during the procedure than those with normal values. The aim of the study was to establish the prevalence, the duration and the risk factors of Ig deficiency after ABMT. Serum Ig levels of 160 children treated with high-dose chemotherapy (HDCT) followed by ABMT for solid tumors were studied prospectively before HDCT and weekly from the day after transplantation until the patients were discharged from the unit, as were the associations of the following covariates: patient characteristics, previous conventional chemotherapy (CCT), conditioning regimens, marrow graft and complications following ABMT. Serum Ig deficiency for at least one isotype was already present before HDCT in half of the children and mean serum Ig values decreased after HDCT. Serum Ig deficiency was early (day 7), inconstant, heterogeneous (IgM deficiency was more frequent and lasted longer) and brief (< 1 month). Children with low Ig values before HDCT were at high risk of profound and prolonged humoral immune deficiency. Previous CCT with more than six different drugs was the main risk factor for low serum IgM values before HDCT, on day 7 and on day 21 post-HDCT. This study shows that Ig replacement therapy could be useful after ABMT provided it is given to the patients defined on the basis of these specific risk factors and serum Ig levels before HDCT.
- 1 August 1996
- Vol. 18 (2) , 325-32
Previous conventional chemotherapy is the principal risk factor for immunoglobulin deficiency during the early post-ABMT period in children.
Humoral immunodeficiency after ABMT may worsen the course of infectious complications as already described in this clinical setting; children with low Ig values of the three isotypes during the first week after ABMT experienced more severe infections during the procedure than those with normal values. The aim of the study was to establish the prevalence, the duration and the risk factors of Ig deficiency after ABMT. Serum Ig levels of 160 children treated with high-dose chemotherapy (HDCT) followed by ABMT for solid tumors were studied prospectively before HDCT and weekly from the day after transplantation until the patients were discharged from the unit, as were the associations of the following covariates: patient characteristics, previous conventional chemotherapy (CCT), conditioning regimens, marrow graft and complications following ABMT. Serum Ig deficiency for at least one isotype was already present before HDCT in half of the children and mean serum Ig values decreased after HDCT. Serum Ig deficiency was early (day 7), inconstant, heterogeneous (IgM deficiency was more frequent and lasted longer) and brief (< 1 month). Children with low Ig values before HDCT were at high risk of profound and prolonged humoral immune deficiency. Previous CCT with more than six different drugs was the main risk factor for low serum IgM values before HDCT, on day 7 and on day 21 post-HDCT. This study shows that Ig replacement therapy could be useful after ABMT provided it is given to the patients defined on the basis of these specific risk factors and serum Ig levels before HDCT.
- 1 April 1996
- Vol. 17 (4) , 485-9
Phase I study of high-dose continuous intravenous infusion of VP-16 in combination with high-dose melphalan followed by autologous bone marrow transplantation in children with stage IV neuroblastoma.
The purpose of the study was to determine the maximum tolerated dose of continuous infusion of high-dose VP-16 in combination with high-dose melphalan (HDM) for conditioning before autologous bone marrow transplantation (ABMT). Thirteen children (median age 27 months) with stage IV neuroblastoma were treated with high-dose VP-16 and HDM followed by ABMT as consolidation treatment. All had previously received conventional chemotherapy with a mean number of six drugs. Surgery of the primary tumor had been performed in 12/13. We performed a dose-escalating study of VP-16 from 1800 mg/m2/72 h with 300 mg/m2/72 h dose increments according to toxicity. VP-16 was administered as a 72-h i.v. infusion. Melphalan (140 mg/m2/day) was administered once as an i.v. push. VP-16 pharmacokinetics were analyzed in 12 patients. Five children received 1800 mg/m2/72 h of VP-16, five received 2100 mg/m2/72 h and three, 2400 mg/m2/72 h. The mean duration of granulocytopenia (< 0.5 x 10(9)/1) was 24 days and thrombocytopenia (< 50 x 10(9)/1) was 36 days. No major infectious complications occurred. Gastrointestinal (GI) toxicity was the dose-limiting toxicity. Five severe manifestations of GI toxicity in three patients led us to consider 2400 mg/m2/72 h as the MTD. The mean VP-16 clearance rate was 17.3 ml/min/m2 with continuous infusion. A mean steady-state plasma concentration of 24.2 micrograms/ml (s.d. = 2) and 28.3 micrograms/ml (s.d. = 1.9) was achieved at the 1800 mg/ml and 2100 mg/m2 dose levels, respectively, GI toxicity is dose limiting when VP-16 at 2400 mg/m2/72 h, is associated with HDM. When given as a continuous i.v. infusion, at 2100 mg/m2/72 h, VP-16 associated with HDM is well tolerated before ABMT in young heavily pre-treated children.
- 1 April 1996
- Vol. 17 (4) , 485-9
Phase I study of high-dose continuous intravenous infusion of VP-16 in combination with high-dose melphalan followed by autologous bone marrow transplantation in children with stage IV neuroblastoma.
The purpose of the study was to determine the maximum tolerated dose of continuous infusion of high-dose VP-16 in combination with high-dose melphalan (HDM) for conditioning before autologous bone marrow transplantation (ABMT). Thirteen children (median age 27 months) with stage IV neuroblastoma were treated with high-dose VP-16 and HDM followed by ABMT as consolidation treatment. All had previously received conventional chemotherapy with a mean number of six drugs. Surgery of the primary tumor had been performed in 12/13. We performed a dose-escalating study of VP-16 from 1800 mg/m2/72 h with 300 mg/m2/72 h dose increments according to toxicity. VP-16 was administered as a 72-h i.v. infusion. Melphalan (140 mg/m2/day) was administered once as an i.v. push. VP-16 pharmacokinetics were analyzed in 12 patients. Five children received 1800 mg/m2/72 h of VP-16, five received 2100 mg/m2/72 h and three, 2400 mg/m2/72 h. The mean duration of granulocytopenia (< 0.5 x 10(9)/1) was 24 days and thrombocytopenia (< 50 x 10(9)/1) was 36 days. No major infectious complications occurred. Gastrointestinal (GI) toxicity was the dose-limiting toxicity. Five severe manifestations of GI toxicity in three patients led us to consider 2400 mg/m2/72 h as the MTD. The mean VP-16 clearance rate was 17.3 ml/min/m2 with continuous infusion. A mean steady-state plasma concentration of 24.2 micrograms/ml (s.d. = 2) and 28.3 micrograms/ml (s.d. = 1.9) was achieved at the 1800 mg/ml and 2100 mg/m2 dose levels, respectively, GI toxicity is dose limiting when VP-16 at 2400 mg/m2/72 h, is associated with HDM. When given as a continuous i.v. infusion, at 2100 mg/m2/72 h, VP-16 associated with HDM is well tolerated before ABMT in young heavily pre-treated children.
- 1 August 1992
- Vol. 10 (2) , 135-41
Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children.
Risk factors for hepatic veno-occlusive disease (HVOD) were analysed in a population of 136 autografted children who received high-dose busulfan (BU) as part of a conditioning regimen. HVOD was diagnosed according to McDonald's clinical criteria. The incidence of HVOD was particularly high in this series (22%) compared with series with other conditioning regimens but the outcome was favorable in 26 patients (87%). Four deaths occurred (13%), one of which was HVOD related. The clinical presentation of HVOD was similar to that described in previous reports. Although statistical analysis failed to demonstrate any factors predictive of outcome, it did identify risk factors for the occurrence of HVOD: these were (1) a total dose of BU exceeding the standard 16 mg/kg dose; (2) the use of three as opposed to two alkylating agents; (3) the sequence of BU administration when given in the conditioning regimen containing three alkylating agents; and (4) concomitant ketoconazole therapy.
- 1 August 1992
- Vol. 10 (2) , 135-41
Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children.
Risk factors for hepatic veno-occlusive disease (HVOD) were analysed in a population of 136 autografted children who received high-dose busulfan (BU) as part of a conditioning regimen. HVOD was diagnosed according to McDonald's clinical criteria. The incidence of HVOD was particularly high in this series (22%) compared with series with other conditioning regimens but the outcome was favorable in 26 patients (87%). Four deaths occurred (13%), one of which was HVOD related. The clinical presentation of HVOD was similar to that described in previous reports. Although statistical analysis failed to demonstrate any factors predictive of outcome, it did identify risk factors for the occurrence of HVOD: these were (1) a total dose of BU exceeding the standard 16 mg/kg dose; (2) the use of three as opposed to two alkylating agents; (3) the sequence of BU administration when given in the conditioning regimen containing three alkylating agents; and (4) concomitant ketoconazole therapy.
- 1 April 1992
- Vol. 9 (4) , 227-33
High-dose busulfan and thiotepa with autologous bone marrow transplantation in childhood malignant brain tumors: a phase II study.
In order to evaluate the effect of intensive combined chemotherapy in pediatric brain tumors, we designed a phase II study of high-dose busulfan and thiotepa followed by bone marrow transplantation (BMT) in children with measurable recurrent brain tumors. As alkylating agents, busulfan and thiotepa were expected to exhibit a steep dose effect and no overlapping extramedullary toxicity. Moreover, both drugs have an excellent distribution into the central nervous system in humans. Since May 1988, 20 children (median age 6 years) have been treated. Busulfan (150 mg/m2/day x 4) given orally was followed by thiotepa (350 mg/m2/day x 3), given as a 1 h i.v. infusion. Cryopreserved bone marrow was reinfused 48 h after completion of chemotherapy. Tumor response was assessed by computed tomography and magnetic resonance imaging 4 to 6 weeks after BMT. Five partial responses were observed (three of six medulloblastomas, one of five ependymomas, one of two primitive neuroectodermal tumors); two patients with medulloblastoma and one with brain stem tumor achieved an objective response. Ten patients had stable disease and one progressive disease. One patient is not evaluable because of early toxic death. Toxicity was high in terms of aplasia and cutaneous, hepatic and neurological complications. The overall response rate of 26% is encouraging since all patients had disease refractory to all conventional therapies.
- 1 April 1992
- Vol. 9 (4) , 227-33
High-dose busulfan and thiotepa with autologous bone marrow transplantation in childhood malignant brain tumors: a phase II study.
In order to evaluate the effect of intensive combined chemotherapy in pediatric brain tumors, we designed a phase II study of high-dose busulfan and thiotepa followed by bone marrow transplantation (BMT) in children with measurable recurrent brain tumors. As alkylating agents, busulfan and thiotepa were expected to exhibit a steep dose effect and no overlapping extramedullary toxicity. Moreover, both drugs have an excellent distribution into the central nervous system in humans. Since May 1988, 20 children (median age 6 years) have been treated. Busulfan (150 mg/m2/day x 4) given orally was followed by thiotepa (350 mg/m2/day x 3), given as a 1 h i.v. infusion. Cryopreserved bone marrow was reinfused 48 h after completion of chemotherapy. Tumor response was assessed by computed tomography and magnetic resonance imaging 4 to 6 weeks after BMT. Five partial responses were observed (three of six medulloblastomas, one of five ependymomas, one of two primitive neuroectodermal tumors); two patients with medulloblastoma and one with brain stem tumor achieved an objective response. Ten patients had stable disease and one progressive disease. One patient is not evaluable because of early toxic death. Toxicity was high in terms of aplasia and cutaneous, hepatic and neurological complications. The overall response rate of 26% is encouraging since all patients had disease refractory to all conventional therapies.